Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

GLP-1 (Glucagon-Like Peptide-1) analogues are synthetic drugs designed ... Enhanced delivery methods continue to expand the accessibility and appeal of GLP-1 analogues. Companies have successfully ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor ... effects of glucagon-like peptide-1 receptor agonists and ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied. Data derived from; Moiz A, et al. Ann Intern Med. 2024 ...

These include: metformin — the most commonly prescribed oral treatment ... insulin and less glucagon, to reduce their blood glucose levels glucagon-like peptide-1 (GLP-1) receptor agonists ...